KNSA Q1 2022 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$32M

Gross Profit

$19M57.9% margin

Operating Income

-$23M-72.4% margin

Net Income

-$25M-78.3% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+71.7%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$231M

Total Liabilities

$65M

Stockholders' Equity

$166M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$0	—
Gross Profit	$19M	-$883,000	+2208.9%
Operating Income	-$23M	-$49M	+52.7%
Net Income	-$25M	-$49M	+49.1%

Revenue Segments

Product

$22M100%